Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 14/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | DUT | P33316 | 1/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129233 | 0.92 | P2RY6 (0.62) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL1129337 | 0.90 | P2RY6 (0.60) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL9805678 | 0.86 | P2RY6 (0.50) | P2RY6DUTP2RY2P2RY4 | |
| SCHEMBL986335 | 0.86 | P2RY6 (0.50) | P2RY6POLA1DUTP2RY2P2RY4 | |
| Phosphoric Acid SCHEMBL27944541 | 0.85 | P2RY6 (0.44) | P2RY6POLA1P2RY2P2RY4 | |
| Phosphoric Acid SCHEMBL7594885 | 0.85 | P2RY6 (0.44) | P2RY6POLA1P2RY2P2RY4 | |
| Triphosphate SCHEMBL27901431 | 0.84 | P2RY6 (0.53) | P2RY6POLA1P2RY2P2RY4 | |
| SCHEMBL51723 | 0.83 | SLC28A1 (0.45) | P2RY6DUTP2RY2P2RY4 | |
| SCHEMBL7394363 | 0.82 | P2RY6 (0.46) | P2RY6POLA1DUTP2RY2P2RY4 | |
| SCHEMBL11383197 | 0.82 | P2RY6 (0.46) | P2RY6DUTP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10086010-B2 | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells | STC.UNM (US) | 2018-10-02 | — | — | US | claimed |
| US-20180125875-A1 | SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2018-05-10 | — | — | US | claimed |
| WO-2015142867-A1 | SYNERGISTIC ENHANCEMENT OF 5-FLUOROURACIL CYTOTOXICITY BY DEOXYURIDINE ANALOGS IN CANCER CELLS | STC.UNM (US) | 2015-09-24 | — | — | WO | claimed |
| WO-2026090505-A1 | FLUOROPYRIMIDINE PARTICLES FOR THE TREATMENT OF CANCER | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2026-04-30 | — | — | WO | disclosed |
| CN-121673349-A | Fluorodeoxyuridine monophosphate prodrug and application thereof in preparation of medicines for treating liver cancer | 北京深蓝泰医药科技有限公司 | 2026-03-17 | — | — | CN | disclosed |
| CN-121673349-A | Fluorodeoxyuridine monophosphate prodrug and application thereof in preparation of medicines for treating liver cancer | 北京深蓝泰医药科技有限公司 | 2026-03-17 | — | — | CN | disclosed |
| EP-4680235-A1 | COMPOSITIONS COMPRISING MELATONIN, 5-FLUOROURACIL AND DIMETHYL SULFOXIDE FOR USE IN THE TREATMENT OF ACTINIC KERATOSIS | RepoCeuticals A/S (DK) | 2026-01-21 | — | — | EP | disclosed |
| WO-2025151105-A1 | 5-FLUOROURACIL AND GENTISIC ACID LOADED NANOPARTICLE COATED WITH BIOTIN | YILDIZ TEKNİK ÜNİVERSİTESİ DÖNER SERMAYE İŞLETME MÜD (TR) | 2025-07-17 | — | — | WO | disclosed |
| CN-111801339-B | 5-Fluorouracil compounds | 纽科利制药公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4534088-A1 | ARFOLITIXORIN FOR USE IN VITAMIN B6-ENHANCED, 5-FLUOROURACIL-BASED CHEMOTHERAPY OF CARCINOMAS | Isofol Medical AB (SE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119614654-A | Enzymatic synthesis method of 2' -fluoro-2 ' -deoxynucleoside-5 ' -triphosphate and application thereof | 华南理工大学 | 2025-03-14 | — | — | CN | disclosed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5470960-A | Antitumor agents | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-11-28 | — | — | US | disclosed |
| US-5411964-A | Phenylalanine-glycine compounds having anti-tumor activity, process for preparation thereof, and pharmaceutical composition containing said compounds | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1995-05-02 | — | — | US | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| EP-0561303-A2 | Conjugates of phenylalanine-glycine with antitumor substances | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-09-22 | — | — | EP | disclosed |
| WO-1993002703-A1 | PRODRUGS ACTIVATED BY TARGETED CATALYTIC PROTEINS | IGEN, INC. (US) | 1993-02-18 | — | — | WO | disclosed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| US-4755388-A | Antiproliferative agent in liposome of cholesterol and phosphatidylglycerol | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1988-07-05 | — | — | US | disclosed |